Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Milademetan in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT03671564Phase 1Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Aug 2018
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of milademetan in acute myeloid leukemia (AML) (3 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Dose Limiting Toxicities at 28 days and Treatment Emergent Adverse Events up to 1 year. Started Aug 2018; status: completed.
02
Drugs
milademetan
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03671564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03671564.